Drug Profile
Trans sodium crocetinate - CervoMed
Alternative Names: Crocetin sodium salt; Sodium crocetinate; Trans sodium crocetinate; Transcrocetinate sodium; TSC; TSC-cpdLatest Information Update: 17 Aug 2023
Price :
$50
*
At a glance
- Originator Office of Naval Research; University of Virginia
- Developer CervoMed; Diffusion Pharmaceuticals; University of Virginia
- Class Antineoplastics; Carotenoids; Dicarboxylic acids; Neuroprotectants; Radiation-sensitising agents; Small molecules; Vascular disorder therapies
- Mechanism of Action Oxygen compound modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Glioblastoma
Highest Development Phases
- Phase III Glioblastoma
- Phase II Interstitial lung diseases; Stroke
- Phase I/II COVID 2019 infections; SARS-CoV-2 acute respiratory disease
- Phase I Brain metastases; Hypoxia; Pancreatic cancer
- Discontinued Peripheral arterial disorders
Most Recent Events
- 16 Aug 2023 EIP Pharma has merged with Diffusion Pharmaceuticals to form CervoMed
- 31 Dec 2022 Diffusion Pharmaceuticals has multiple patents pending for Trans sodium crocetinate in USA and other multiple countries as of December 2022
- 31 Dec 2022 Diffusion Pharmaceuticals has multiple patents protection for Trans sodium crocetinate in USA and other multiple countries as of December 2022